| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Interest expense | 5,960 | - | ||
| Total other income (expense) | -294,851 | -55,368 | ||
| Net loss attributable to common stockholders | -4,856,051 | -4,276,502 | ||
| Earnings per share, basic | -5.82 | -5.13 | ||
| Earnings per share, diluted | -5.82 | -5.13 | ||
| Weighted average number of shares outstanding, basic | 833,683 | 833,654 | ||
| Weighted average number of shares outstanding, diluted | 833,683 | 833,654 | ||
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)